Navigation Links
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Date:7/28/2011

randomized, placebo-controlled trial in healthy volunteers.  In the multiple ascending dose portion of the study, doses of 250 mg, 500 mg, and 750 mg given three times daily, as well as 1,000 mg given twice daily, were administered over the course of 14 days.  There were eight healthy volunteers (six receiving active compound, two receiving placebo) in each dose group.  Study endpoints included safety and tolerability together with pharmacokinetic and pharmacodynamic parameters consisting of measures of both plasma and urinary 5-HIAA.  Data from the study showed that LX1033 produced a statistically significant decrease in both plasma and urinary 5-HIAA as compared to placebo at all doses tested.  Notably, the plasma measures of 5-HIAA in the recent study were obtained from a simple morning blood draw and correlated with results obtained by the traditional 24-hour urine collection method.

"The favorable safety and tolerability profile for LX1033, together with its local site of action within the gastrointestinal tract and ability to potently reduce serotonin synthesis, make this a very attractive candidate for clinical trials in IBS-d, where the need for new treatments is great," said Dr. Pablo Lapuerta, senior vice president and chief medical officer at Lexicon.  "We look forward to advancing this drug into a Phase 2 trial where we can examine safety and efficacy in IBS-d."

About LX1033

LX1033 is an orally-delivered drug candidate for IBS that inhibits tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.  LX1033 is designed to act locally in the gastrointestinal (GI) tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain.  

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human diseas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
3. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
4. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
(Date:12/17/2014)... December 17, 2014 , ... than a hub of information concerning the biopharmaceutical Group,s national ... A further addition to the recently launched institutional website that ... now been enriched by a new chapter in the fascinating ... A richly detailed and panoramic hub on the world of ...
(Date:12/17/2014)... -- PCCA received the Autism Hope Alliance,s (AHA) ... seal for best practices in meeting needs in ... materials and goods that meet strict criteria and ... by autism often have unique physical or psychological ... in food and medicine – for instance casein, ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
(Date:12/20/2014)... DePuy Pinnacle hip lawsuits ( ... the artificial hip system was defectively designed continue ... Bernstein Liebhard LLP reports. According to an Order ... on December 2nd, counsel in 10 DePuy Pinnacle ... on November 19, 2014, with depositions to conclude ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Doctor’s Office ... for the better part of a decade. They’ve treated ... a better, faster healthcare alternative to the Paramus ... announce three new additions to their staff of top-notch board ... Jill Zeiger MD. These new doctors will work ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... Entertainment has caused quite a stir, not only in Hollywood, ... Times on December 18th , the ripples of that attack ... level executives’ very jobs at risk. But they are ... email correspondences exposed could be in for some embarrassing times ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Twin ... protection education event in the nation! Over 250 financial ... the minute information on the industry, get motivated to ... of real people facing and overcoming the challenges of ... all across the nation came together to attend The ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays ... the wayside until Christmas and the New Year are over. ... that burning desire to just escape it all and get ... Telluride with a no-fuss, affordable package. Montrose Days Inn will ... and ensure that all accommodations are met. Plus, everyone has ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... biopsy is a reasonably safe and accurate method for the ... the April issue of the Journal of the American ... criticized shave biopsies for not providing accurate T (tumor) stage ... study to determine the impact of shave biopsies on the ...
... May, 2011 Elsevier, the leading global publisher ... services, announced today a partnership agreement with Medical ... medical simulation and health care learning technologies. The ... care education product that combines Elsevier,s nursing education ...
... , SUNDAY, May 22 (HealthDay News) -- The ... affects the lungs and digestive system, seems to be ... cystic fibrosis patients born today live to their mid-30s, ... before their 10th birthday, while others live into their ...
... that allowing full access to personal medical records increases ... Published early online in Cancer , a peer-reviewed ... that providing accurate information to patients through medical records ... their physicians. Most cancer patients say they are ...
... Hospital Boston and collaborators at other institutions has provided ... produce new bone in response to mechanical stresses, such ... new strategies for treating diseases characterized by low bone ... in children. The research team, led by Matthew ...
... SATURDAY, May 21 (HealthDay News) -- As summer approaches ... illnesses, experts say. "We are not invincible when ... McDermott, an athletic trainer with the University of Tennessee ... (KSI) Medical and Science Advisory Board, in a news ...
Cached Medicine News:Health News:Shave biopsy is a safe and acceptable method for initial evaluation of melanoma 2Health News:Elsevier and METI collaborate to offer simulation technology for health science curriculums 2Health News:Genes Tied to Severity of Cystic Fibrosis Identified 2Health News:Access to personal medical records increases satisfaction among new cancer patients 2Health News:A direct path for understanding and treating brittle bones 2Health News:A direct path for understanding and treating brittle bones 3Health News:Keeping Cool in the Heat 2
...
Dual-sided, Interhemispheric Grid Electrode with 16 Contact Leads; Cortical Grid Electrode with 16 Contact Leads; Pediatric Grid Electrode with Flex Connector, 0.5 cm spacing...
... cortical strip electrodes are extra thin ... through a burr hole. The narrow ... enables quick and secure attachment to ... Integra Epilepsy electrode designs, they are ...
... Epilepsy Flex Connector represents a ... of epilepsy electrodes. This versatile ... and attachment to the electrode ... is provided with a peel-away ...
Medicine Products: